Article

Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn's disease treatment

Department of Medicine, Division of Gastroenterology, Helsinki University Central Hospital, Helsinki, Finland.
Scandinavian Journal of Gastroenterology (Impact Factor: 2.33). 03/2010; 45(3):325-31. DOI: 10.3109/00365520903483650
Source: PubMed

ABSTRACT Serial monitoring data for faecal calprotectin and lactoferrin during Crohn's disease (CD) therapy are scarce. The aim of this research was to study the behaviour of faecal biomarkers during CD therapy.
Adult CD patients (n = 19) needing therapy enhancement were prospectively recruited. The simple endoscopic score for Crohn's disease (SES-CD) was administered before and 4-6 months after therapy. At baseline and at 2-3 and 4-6 months, patients provided faecal samples for measurements of calprotectin and lactoferrin.
Of 19 patients, seven were endoscopic responders, three were partial responders and nine were non-responders. During therapy, both faecal-biomarker concentrations decreased significantly in responders: median calprotectin from 1282 microg/g (range 156-2277 microg/g) to 73 microg/g (range 7-2222; P = 0.005) and lactoferrin from 233 microg/g (range 2.8-802 microg/g) to 0.0 microg/g (range 0.0-420 microg/g; P = 0.005), and these changes correlated significantly with changes in the SES-CD. In non-responders, changes in faecal biomarkers were non-significant: calprotectin decreased from 1017 microg/g (range 53-3928 microg/g) to 223 microg/g (range 35-15330 microg/g; P = 0.594) and lactoferrin from 22.5 microg/g (range 2.1-629 microg/g) to 13.0 microg/g (range 3.5-1259 microg/g; P = 0.515).
The faecal neutrophil-derived proteins calprotectin and lactoferrin are reliable surrogate markers of mucosal improvement. Endoscopic responders achieved normalization of faecal biomarkers, whereas in the majority of endoscopic non-responders these markers remained abnormal.

Download full-text

Full-text

Available from: Kaija-Leena Kolho, Jul 05, 2015
0 Followers
 · 
266 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Il morbo di Crohn (Crohn’s disease, CD) e la rettocolite ulcerosa (ulcerative colitis, UC) sono le principali forme cliniche delle malattie infiammatorie intestinali (inflammatory bowel disease, IBD). In questo gruppo di patologie i marcatori di laboratorio possono essere utilizzati per la diagnosi, per valutare l’attività di malattia, per predire le fasi di esacerbazione e per valutare gli effetti della terapia. È possibile distinguere tra marcatori sierici e fecali. La proteina C reattiva è il marcatore sierico maggiormente studiato e utilizzato, in quanto ha dimostrato di essere quello dotato complessivamente delle migliori prestazioni. I marcatori fecali dovrebbero essere maggiormente specifici nell’identificare le flogosi di origine intestinale e tra essi lattoferrina e calprotectina sono i dosaggi più promettenti. Altri importanti marcatori sierologici sono di natura anticorpale. I più conosciuti sono gli anticorpi anti-Saccharomyces cerevisiae (anti-Saccharomyces cerevisiae antibodies, ASCA), ma la lista è in rapida espansione, come gli anticorpi anti-antigeni batterici recentemente identificati (anti-outer membrane porin C, anti-I2, anti-flagellin), gli anti-glicani (anti-chitobioside IgA, anti-laminaribioside IgG, anti-mannobioside IgG) e gli anticorpi diretti contro i due maggiori epitopi degli oligomannani sintetizzati chimicamente. Per quanto riguarda gli autoanticorpi, gli anti-citoplasma dei neutrofili (pattern p-ANCA atipico) sono classicamente utilizzati nel differenziare CD da UC. Recentemente è stata particolarmente sottolineata la specificità degli anti-pancreas verso il CD. I nuovi marcatori si possono considerare complementari ad ASCA e ANCA non soltanto per incrementare la sensibilità diagnostica e differenziare CD da UC, ma anche perché risultano utili a identificare il fenotipo della malattia e a predirne il rischio di complicazioni e di ricorrere alla chirurgia.
    Rivista Italiana della Medicina di Laboratorio 09/2013; 9(3). DOI:10.1007/s13631-013-0012-4
  • [Show abstract] [Hide abstract]
    ABSTRACT: Die Durchführung einer individualisierten Therapie chronisch-entzündlicher Darmerkrankungen bedarf einer intensiven Überwachung, insbesondere bei Patienten mit Risikoprofil für schwerwiegende Verläufe sowie nachweisbarer Entzündung. Eine rein klinische Evaluation hat eine Reihe von Limitationen, so dass weitere Instrumente zur Erfassung der Entzündung notwendig sind. Zu den nichtinvasiven Maßnahmen der Therapieüberwachung gehören insbesondere das CRP bei Morbus Crohn sowie fäkale Stuhlmarker wie Calprotectin für Morbus Crohn und Colitis ulcerosa, die teilweise eine sehr gute Korrelation zur endoskopischen Aktivität aufweisen. Zudem korrelieren Veränderungen dieser Parameter mit einem Therapieansprechen und weisen auf eine erhöhte Rezidivgefahr hin. Die Endoskopie bleibt allerdings weiterhin eine wichtige Methode in der Therapieüberwachung, die gerade bei wichtigen Therapieentscheidungen herangezogen werden muss. Nach Therapieeskalation oder auch -deeskalation kann man sich in der Beurteilung der Effektivität oft auf die Überprüfung von CRP und/oder fäkales Calprotectin beschränken und somit erneute endoskopische Untersuchungen vermeiden. Weniger gut evaluiert in der Therapieüberwachung sind Ultraschall, MRT und Kapselendoskopie, so dass diese eher in Einzelfällen herangezogen werden. Somit stehen insbesondere mit CRP und Calprotectin neben der Endoskopie wichtige Hilfsmittel zur Verfügung, um die Therapie chronisch-entzündlicher Darmerkrankungen nachhaltig zu optimieren.
    Der Gastroenterologe 08/2014; 8(3). DOI:10.1007/s11377-012-0723-5
  • [Show abstract] [Hide abstract]
    ABSTRACT: The use of faecal calprotectin as a surrogate marker for intestinal inflammation is emerging. However, the data on faecal calprotectin during maintenance therapy in children with inflammatory bowel disease, IBD, are sparse. Our aim was to study faecal calprotectin levels in paediatric IBD during clinically quiescent disease and to investigate if high levels were associated with a flare-up of the disease. Faecal calprotectin level was measured in 72 children with paediatric IBD in clinical remission (median age 13 years). Of these, 37 children had been in clinical remission for more than a year, 20 for 6-12 months and 15 for 3 to <6 months. The clinical outcome of the patients was followed up to the first relapse or up to 12 months. When in clinical remission, 35% (25/72) of the children had normal faecal calprotectin (<100 microg/g) and 13% (9/72) a very high level (>1000 microg/g) while not reporting symptoms. A clinical relapse occurred in 35% (25/72) during the subsequent 12 months. When in clinical remission, the predictive value of faecal calprotectin for an overt relapse was low ranging from 0.396 to 0.429 for faecal calprotectin values >100 microg/g or >1000 microg/g, respectively. The negative predictive value was 0.75 for values <100 microg/g. In paediatric IBD, subjective symptoms and clinical assessment associate poorly with the levels of faecal calprotectin. During maintenance medication in colonic disease, the probability of staying in clinical remission for a subsequent year is high if faecal calprotectin value is low.
    Scandinavian Journal of Gastroenterology 04/2010; 45(7-8):872-7. DOI:10.3109/00365521003782389 · 2.33 Impact Factor